SA
ARWR logo
Arrowhead Pharmaceuticals, Inc.(ARWR)
Closing price · checked 8:16 PM ETAbout this dataData status
$41.37▼-2.28 (-5.22%)
Extended:$41.40+0.03 (+0.07%)· 8:16 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →
ARWR logo

ARWR EV to Sales

Current (TTM)12.55×
ARWR EV/Sales (21.84× → 12.55×)
Powered by
High-resolution chart · PNG

What is ev to sales?

Enterprise value to sales ratio.

ARWR ev to sales history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

Arrowhead Pharmaceuticals Inc EV to Sales — Annual fiscal periods
Period endingEV to SalesChange
22.6416×+295.12%
5.7304×−99.34%
864.3886×+6,524.96%
13.0475×−8.22%
14.2165×−68.88%
45.687×−4.62%
47.8982×+233.66%
14.3554×−85.32%
97.8104×+943.36%
9.3746×−99.59%
2,309.1738×+252.94%
654.2634×−79.60%
3,207.3488×+679.07%
411.691×+119.60%
187.4716×+163.49%
71.1486×−27.92%
98.7143×+1,168.59%
7.7814×−68.51%
24.7102×−80.77%
128.4872×−41.79%
220.7141×+143.94%
90.4798×−72.52%
329.2346×—
0×−100.00%
282.2832×+289.44%
72.4851×+58.91%
45.6128×+46.76%
31.0794×+4.81%
29.6524×+35.77%
21.8406×—

Frequently asked questions: ARWR ev to sales

What is Arrowhead Pharmaceuticals Inc (ARWR)'s current ev to sales?

Arrowhead Pharmaceuticals Inc (ARWR)'s latest reported ev to sales (TTM) is 12.55× as of Nov 22, 2026. Enterprise value to sales ratio.

How much historical ev to sales data is available for ARWR?

Stock Alarm Pro provides 30 dated annual fiscal periods observations for Arrowhead Pharmaceuticals Inc (ARWR)'s ev to sales, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare ARWR's ev to sales to peers or set an alert?

You can open ARWR's ev to sales in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on ARWR delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.